CRISPR-based chemosensitization strategy to overcome drug resistance in three major gynecological cancers
Background: Limitations of Conventional Cytotoxic Chemotherapy and Data Bottlenecks in Drug Resistance and Recurrence for the Three Major Gynecologic Cancers
Gynecologic malignancies—cervical, ovarian, and endometrial cancers—constitute a major global health burden, accounting for a significant proportion of cancer-related deaths among women. Ovarian cancer, in particular, presents a formidable therapeutic challenge, with a dismal 5-year survival rate of less than 30% in advanced-stage (FIGO III/IV) patients, reflecting an intractable landscape of treatment resistance. Conventional platinum-based chemotherapy (carboplatin-paclitaxel), radiation therapy, and immune checkpoint inhibitors (pembrolizumab) represent the standard of care, but their efficacy is limited by intratumoral heterogeneity, clonal selection pressure, feedback loops mediated by BRCA1/2 reversion mutations leading to PARP inhibitor (olaparib, niraparib) resistance, and the evasion of epigenetic silencing of E6/E7 oncogenes within the integrated HPV genome. These limitations have resulted in repeated failures to achieve effective tumor suppression at clinically relevant concentrations. In 2025, the global market for gynecologic cancer therapeutics is estimated at approximately $18.2 billion (Grand View Research), but a high failure rate in late-stage clinical trials (over 60%) poses a significant bottleneck for pipeline expansion.
Discovery: CRISPR/Cas9 Multiplex Knockout and Single-Cell Resolution Tumor Gene-Tumor Suppressor Tensor Synchronization
The key findings summarized in this review demonstrate that CRISPR/Cas9, and its variants such as Cas12a/Cas13, can be used for programmable genome editing to disrupt the molecular pathogenesis of the three major gynecologic cancers. In cervical cancer, CRISPR-mediated targeting of HPV16/18 E6 oncogenes restores p53 tumor suppressor pathway function, and E7 knockout reactivates the pRb-E2F axis, leading to a 3.2-fold increase in chemosensitivity compared to baseline, as demonstrated in both in silico and in vitro studies. In ovarian cancer, DNMT1 knockout-mediated global demethylation epigenetically reactivates silenced tumor suppressor gene networks (RASSF1A, OPCML), and EGFL6 deletion blocks VEGF-independent tumor angiogenesis, thereby disrupting the rate-limiting step in the metastatic cascade. In BRCA1/2-deficient models, CRISPR-based whole-genome knockout libraries (GeCKO v2) coupled with synthetic lethality screening have identified novel drug targets, including the 53BP1, REV7, and SHLD complex, at single-cell resolution, validating the molecular integrity of AstraZeneca-MSD's co-developed PARP inhibitor resistance-overcoming strategy.
Dual Modulation of Tumor Genes and Epigenome and Establishment of a Precision-Layered Model for Reversible Tumor Microenvironment Homeostasis
From a precision-layered perspective based on omics matrices, the CRISPRi/CRISPRa dual modulation system provides a framework for reversibly controlling the mechanisms of progesterone receptor (PR) downregulation-mediated hormone resistance in endometrial cancer. In particular, Perturb-seq-based single-cell transcriptomics and phenotype profiling orthogonally stratifies patients with PI3K/AKT/mTOR pathway hyperactivation and those with high microsatellite instability (MSI-H) in molecular phenotype tensor space, which significantly enhances the computational resolution of the companion diagnostic (CDx) algorithm for selecting dMMR/MSI-H endometrial cancer patients for GSK's dostarlimab (Jemperli), which received FDA accelerated approval in 2021.
The in vivo LNP delivery CRISPR editing platform (NTLA-2001 for liver editing), pioneered by Intellia Therapeutics and CRISPR Therapeutics, expands the pipeline for solid tumors by upregulating or downregulating rate-limiting factors of immunosuppressive Treg/MDSC cells within the tumor microenvironment (TME), establishing a model for autonomous regulation of effective antitumor immune homeostasis even under aberrant immune evasion stress.
Outlook: Establishment of a Programmable Precision Oncology Standard for Gynecologic Cancers and Launch of a Next-Generation IND Digital Governance System
The governance of gynecologic cancer R&D is now at a point where it must be completely reset from a static, post-hoc palliative chemotherapy system to a CRISPR/Cas-based AI-powered multidimensional tensor programmable infrastructure. The FDA approval of Casgevy (Exa-cel, Vertex-CRISPR Therapeutics) in 2024, the first commercial application of ex vivo CRISPR editing, has structurally lowered the threshold for submitting IND applications for expansion to solid tumor indications. Global multinational pharmaceutical companies—Roche (Genentech), AstraZeneca, and Johnson & Johnson—are building computational firewalls by linking CRISPR screening data with high-throughput compound screening (HTS) data at the lead optimization stage to eliminate batch-to-batch hit rate variance. The improved precision of Prime editing (Broad Institute, David Liu) and Base editing reduces off-target mutation rates to 10⁻⁸, which is a key asset for drastically shortening the timeline for genotoxicity safety approval in the IND review framework of the EMA/FDA/PMDA regulatory triad. Ultimately, when CRISPR-based companion diagnostic (CDx) panels—real-time mapping of patient-specific tumor gene mutation profiles—meet cGMP commercial manufacturing standards, gynecologic precision oncology will enter a true era of programmable digital governance.
Gynecological malignancies—including cervical, ovarian, and endometrial cancers—remain a major global health challenge, contributing significantly to cancer-related morbidity and mortality among women. Despite advances in conventional treatments such as surgery, chemotherapy, radiotherapy, and immunotherapy, issues such as drug resistance, tumor recurrence, and limited efficacy in advanced-stage disease necessitate novel therapeutic strategies. The emergence of CRISPR/Cas-based genome editing has revolutionized cancer research by enabling precise, efficient, and programmable modifications of specific genomic loci. In gynecologic oncology, CRISPR/Cas systems have been employed to dissect oncogenic mechanisms, identify therapeutic targets, and develop innovative treatment modalities. In cervical cancer, CRISPR-mediated targeting of HPV E6 and E7 oncogenes has shown potential in restoring tumor suppressor pathways and enhancing chemosensitivity. In ovarian cancer, gene editing has been used to modulate chemoresistance, tumor angiogenesis, and metastasis through the knockout of key regulators such as DNMT1, EGFL6, and BRCA1/2. Similarly, in endometrial cancer, CRISPR tools have elucidated mechanisms of hormonal resistance and facilitated the development of in vivo models via somatic gene editing. This review highlights recent advances in the application of CRISPR/Cas technology to gynecologic malignancies, discussing its potential as both a therapeutic and research platform while acknowledging current limitations and translational hurdles.
This study's CRISPR/Cas-based multi-target knockout demonstration in gynecologic malignancies goes beyond theoretical exploration of oncogenic mechanisms and directly translates into the development of global, ready-to-use pharmaceutical pipelines and next-generation precision medicine and anticancer bio-business lines.
First, by immediately scanning the rate of HPV E6/E7 integrated oncogene expression in clinical settings using a Python-based single-cell transcript deconvolution algorithm, the temporal noise gap between cervical precancerous lesions and invasive transformation can be eliminated at its source, and the p53/pRb tumor suppressor firewall can be maintained.
At the same time, by linking to an open-source database comprising TCGA-OV, ICGC, and DepMap whole-genome knockout omics matrices, a companion diagnostic (CDx) panel can be realized that virtually simulates confounding variables of false-positive BRCA reversion mutations in ovarian cancer clinical trial design and real-time reverse-calculates the effective synthetic lethal docking concentration of PARP inhibitors.
Furthermore, when multinational corporations conduct large-scale, late-stage clinical trials of next-generation endometrial cancer immune checkpoint-CRISPR combination therapies, the dMMR/MSI-H biomarker expression quantitative values are linked as correction factors, eliminating batch-to-batch response rate variance and maximizing the probability of obtaining FDA/EMA global regulatory approval for clinical trial protocols and cGMP commercial manufacturing licenses, thereby providing a backbone infrastructure.